Mestag Therapeutics was founded in 2020 by leading scientists, drug developers and investors to pioneer new medicines for people affected by inflammatory disease and cancer.
Our approach builds on recent data which points to resident cells called fibroblasts as playing a key role in driving disease. Mestag’s mission is to lead this emerging field in developing impactful precision medicines for patients through our understanding of activated fibroblast populations and their influence on immune effector cells.
Our company was created by global thought-leaders in fibroblast biology, is supported by experienced international investors and is powered by our team of scientists based in Cambridge, UK.
Mestag is backed by leading global life sciences & healthcare investors, SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc.
SV Health Investors has over $3 billion in capital commitments raised across ten private venture capital funds and one publicly listed fund. SV has a 25-year track record in the US and Europe with offices in Boston and London. This investment has been committed from SV’s first dedicated biotechnology focussed fund, the Impact Medicine Fund, which invests in precision medicine therapeutics in areas of high unmet need.
JJDC is the strategic venture capital arm of Johnson & Johnson and pursues opportunities to solve critical healthcare needs. Their portfolio companies benefit from the full global capabilities of Johnson & Johnson as they collaborate to drive innovation. JJDC finds transformative ideas and helps them mature into real solutions for today’s patients.